Irisin a Novel Metabolic Biomarker: Present Knowledge and Future Directions.
Ilse Yessabel Martinez MunozEneida Del Socorro Camarillo RomeroJose de Jesus Garduno GarciaPublished in: International journal of endocrinology (2018)
The rising prevalence of chronic diseases such as type 2 diabetes and cardiovascular diseases owing to fat mass excess has been described. In recent years, muscle function/dysfunction has become relevant in metabolic homeostasis. Irisin was described as an exercise-induced myokine. It is the product of type I membrane protein cleavage encoded by the fibronectin type III domain containing 5 (FNDC5) gene. The main beneficial function attributable to irisin is the change of subcutaneous and visceral adipose tissue into brown adipose tissue, with a consequential increase in thermogenesis. Irisin has also been described as a hormone that may have a key role in glucose homeostasis. The way the association of type 2 diabetes with obesity occurs is not fully understood. In recent years, the possible pathways through which irisin could interact with other organs such as the brain or bone have been described. The present paper intends to review the new findings and possible new directions in irisin research.
Keyphrases
- adipose tissue
- insulin resistance
- type diabetes
- type iii
- cardiovascular disease
- high fat diet
- healthcare
- metabolic syndrome
- skeletal muscle
- high fat diet induced
- weight loss
- oxidative stress
- glycemic control
- body mass index
- risk factors
- gene expression
- genome wide
- transcription factor
- blood brain barrier
- weight gain
- physical activity
- copy number
- white matter
- fatty acid
- postmenopausal women
- functional connectivity